Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Company Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, that specializes in the discovery and development of therapies targeting cellular metabolism in both oncology and rare genetic diseases. The company’s scientific approach centers on modulating metabolic processes to restore normal cellular function or to inhibit disease-specific metabolic pathways. Since its founding in 2008, Agios has built a research platform that integrates molecular biology, genetics, and chemistry to advance precision medicines from early research through regulatory approval.

Agios’ commercial portfolio includes Tibsovo® (ivosidenib), an oral inhibitor of mutant IDH1 used to treat certain forms of acute myeloid leukemia (AML) and cholangiocarcinoma, and Pyrukynd® (mitapivat), a first-in-class pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. These products reflect the company’s commitment to addressing areas of significant unmet medical need through tailored therapies that leverage its expertise in enzyme regulation.

Beyond its marketed therapies, Agios maintains a robust pipeline of investigational candidates targeting metabolic drivers of cancer and rare diseases. Research collaborations with global pharmaceutical partners support late-stage development in additional hematologic malignancies and solid tumors, as well as expansion into neurometabolic disorders. The company’s research operations and strategic partnerships span North America, Europe, and Asia, reflecting its goal of making novel metabolic medicines accessible to patients worldwide.

Co-founded by leaders in metabolic biology and biochemistry, Agios completed its initial public offering in 2013 and has since evolved into a wholly owned affiliate of Servier following a strategic transaction in early 2023. Under the leadership of President and Chief Executive Officer Brian Goff, Agios continues to invest in scientific innovation, manufacturing capabilities, and global regulatory activities, positioning itself at the forefront of metabolic therapy development.

Key Stats

• Today's Range: $35.12 to $36.15
• 50-Day Range: $27.32 to $36.06
• 52-Week Range: $23.42 to $62.58
• Volume: 258,713 shs
• Average Volume: 652,247 shs
• Market Capitalization: $2.09 billion
• P/E Ratio: 3.21
• Dividend Yield: N/A
• Price Target: $58.60
• Consensus Rating: Moderate Buy

Agios Pharmaceuticals Stock Analysis - MarketRank™

Agios Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 586th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agios Pharmaceuticals is 3.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agios Pharmaceuticals is 3.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.52.

Price to Book Value per Share Ratio

Agios Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.79% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agios Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Agios Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.13

Percentage of Shares Shorted

7.79% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.54

News Sentiment

Agios Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Agios Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,305,213.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Agios Pharmaceuticals is held by insiders.

AGIO Stock Analysis - Frequently Asked Questions

How have AGIO shares performed this year?

Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of 2025. Since then, AGIO shares have increased by 9.7% and is now trading at $36.0550.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.25. The biopharmaceutical company earned $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative trailing twelve-month return on equity of 2.75%.
Read the conference call transcript.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGIO
• CIK: 1439222
• Web: www.agios.com
• Phone: (617) 649-8600
• Fax: N/A
• Employees: 390
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $58.60
• High Stock Price Target: $71.00
• Low Stock Price Target: $51.00
• Potential Upside/Downside: +62.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $11.24
• Trailing P/E Ratio: 3.21
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $673.72 million
• Net Margins: 1,798.26%
• Pretax Margin: 1,917.72%
• Return on Equity: -2.75%
• Return on Assets: -2.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.50
• Quick Ratio: 17.93

Sales & Book Value

• Annual Sales: $36.50 million
• Price / Sales: 57.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $27.02 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 57,920,000
• Free Float: 55,425,000
• Market Cap: $2.09 billion
• Optionable: Optionable
• Beta: 0.73